Phio Pharmaceuticals Corp. (PHIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 20K 40K 60K Q1 '16: 10K Q2 '16: 9K Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 15K Q1 '18: 23K Q2 '18: 58K Q3 '18: 57K Q4 '18: 0 Q1 '19: 21K Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q2 '16 Q1 '17 Q4 '17 Q3 '18 Q2 '19 Q1 '20 Q4 '20

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -3.7M Q4 '21: -3.5M Q1 '22: -2.6M Q2 '22: -2.5M Q3 '22: -3.6M Q4 '22: -2.7M Q1 '23: -3.6M Q2 '23: -2.5M Q3 '23: -2.8M Q4 '23: -1.9M Q1 '24: -2.2M Q2 '24: -1.9M Q3 '24: -1.6M Q4 '24: -1.7M Q1 '25: -1.9M Q2 '25: -2.3M Q3 '25: -2.5M Q4 '25: -2.5M Q1 '26: -4.2M Q2 '26: -4.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -3.7M Q4 '21: -3.5M Q1 '22: -2.6M Q2 '22: -2.5M Q3 '22: -3.6M Q4 '22: -2.7M Q1 '23: -3.6M Q2 '23: -2.5M Q3 '23: -2.8M Q4 '23: -1.9M Q1 '24: -2.2M Q2 '24: -1.8M Q3 '24: -1.5M Q4 '24: -1.6M Q1 '25: -1.8M Q2 '25: -2.2M Q3 '25: -2.4M Q4 '25: -2.4M Q1 '26: -4M Q2 '26: -4.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -2.9M Q4 '21: -2.5M Q1 '22: -3.5M Q2 '22: -2.4M Q3 '22: -3.5M Q4 '22: -2.7M Q1 '23: -2.7M Q2 '23: -2.8M Q3 '23: -2.9M Q4 '23: -2.4M Q1 '24: -2M Q2 '24: -1.8M Q3 '24: -2M Q4 '24: -1.4M Q1 '25: -1.3M Q2 '25: -2.5M Q3 '25: -2.1M Q4 '25: -2.1M Q1 '26: -4M Q2 '26: -4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -2.9M Q4 '21: -2.5M Q1 '22: -3.6M Q2 '22: -2.4M Q3 '22: -3.5M Q4 '22: -2.7M Q1 '23: -2.7M Q2 '23: -2.8M Q3 '23: -2.9M Q4 '23: -2.4M Q1 '24: -2M Q2 '24: -1.8M Q3 '24: -2M Q4 '24: -1.4M Q1 '25: -1.3M Q2 '25: -2.5M Q3 '25: -2.1M Q4 '25: -2.1M Q1 '26: -4M Q2 '26: -4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 400M 800M 1.2B Q1 '21: 10.7M Q2 '21: 13.5M Q3 '21: 13.5M Q1 '22: 1.1M Q2 '22: 1.1B Q3 '22: 1.1M Q1 '23: 1.1M Q2 '23: 192.1K Q3 '23: 271.1K Q1 '24: 4.6M Q2 '24: 510.2K Q3 '24: 990K Q1 '25: 4.3M Q2 '25: 4.8M Q3 '25: 5.5M Q1 '26: 11.6M Q2 '26: 11.6M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-30.00 -20.00 -10.00 0.00 10.00 20.00 30.00 Q3 '20: -6.70 Q4 '20: -2.48 Q1 '21: -1.47 Q2 '21: -1.33 Q3 '21: -1.21 Q4 '21: -12.45 Q1 '22: -14.47 Q2 '23: -21.96 Q3 '23: -29.07 Q4 '23: -28.15 Q1 '24: -25.47 Q2 '24: -15.82 Q3 '24: -7.11 Q4 '24: -6.48 Q1 '25: -6.42 Q2 '25: -3.25 Q3 '25: -2.15 Q4 '25: -1.45 Q1 '26: -1.38 Q2 '26: -1.29 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.